Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Wound Management Technologies — Investor Presentation (November 2010)
17 slides from Sanara Medtech's investor presentation, Nov 12, 2010
Slide 1: Wound Management Technologies, Inc.
Wound Mana’ TECHNOLOGIES, INC. gement “The clinical results we have observed have validated the science behind the product. ! would highly recommend CellerateRX® to any conscientious wound care provider.“
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this Presentation are made as of the date of this Presentation unless stated otherwise and are subject to change, completion, or amendment without notice. Neither the delivery of this Presentation at any time shall under any circumstances create an implication tha
Slide 3: Wound Management Markets
Wound Management Markets Wound Management’s unique patented CellerateRX® products address the very large and growing advanced wound care markets. > The U.S. Advanced Wound Care Market in 2007 totaled @ $3.0B and is projected to double by 2013 Total U.S. Advanced Wound Care Market $ Millions 2008 201
Slide 4: Diabetes: A Worldwide Epidemic, a Prime Market for CellerateRX
Ket ip iabates — A Worldwide Epidemic, a iabetes — A Worldwide Epidemic, a Prime Market for CellerateRX According to the IDF, approximately 285M people will live with . diabetes in 2010. WHO projects this to grow to 360M by 2030 Diabetes affects approximately 24M Americans; 57M are pre- iq diabetic
Slide 5: Wound Care: CellerateRX advantage in Activated Collagen
Wound Care Innovations, LLC §@SW2ge/4en The CellerateRX® advantage is in the patented, Activated Collagen™ fragments (CRXa™) combined with the properties of the Type |, bovine-sourced, material. CellerateRX ® provides the wound site with a form of collagen that is unique as it is ready to be used im
Slide 6: Why CellerateRX?
Why CellerateRX? > CellerateRX® is available in powder and gel forms > /tis a unique, patented, activated collagen that delivers immediate benefits to the wound Cost-effective > Both in product cost and in the cost of labor involved v v Biocompatible and biodegradable Unprecedented range of use in e
Slide 7: CellerateRX Regulatory Status
we | 9995 WNDM P0009, ~| CellerateRX® Regulatory Status yo Yer v Reimbursed by Medicare Part B v Regulated as a medical device - \ > CellerateRX® does not require a prescription ) > FDA cleared for all wounds* including: Except 3” degree bums v Certifications in process: > ISO 9001:2008/13485:2003/C
Slide 8: Sales Team in Place
Sales Team in Place > Poised for Growth: having completed evidence- based studies , Wound Management developed its sales channel plan and engaged sales and marketing executives in April 2010. > Growth from: Growing brand recognition New direct reps in Florida and Texas Management of independent rep
Slide 9: % of States In
11/11/2010 % of States In Order Volume Category $500 n 22.60% $5,000 32.10% $50,000 7 13.20% $50,000 to $500,000 2 3.80% Copyright © 2010 Wound Management Technologies Inc.
Slide 10: CellerateRX International Sales Agreements
CellerateRX® International Sales Agreements » Middle East (Distributor Signed in 2009) » Lebanon (First sale was in 1Q 2010) » Pending 2010 Sales: Saudi Arabia, Iran, Dubai, Qatar > Europe (Italy Distributor Signed in 2009, more under discussion) > CE registration pending > South Africa (Distributor
Slide 11: Help for All Ages... More than just Evidence Based Studies
Help for All Ages... More than just Evidence Based Studies Leona Lake — 99 years old. In 2009 she was seeking help to heal a bad wound from radiation treatment. She went months with no positive results from other products and had to stop her pool exercise. After 5 weeks of using CellerateRX, the wou
Slide 12: Biotech Pipeline
Biotech Pipeline Resorbable Bone Wax & Bone Void Filler products > $1.4B Worldwide Bio Materials Market >» Resorbable orthopedic hemostat used to stop blood flow & delivery system for osteogenic / osteoinductive orthopedic products > Budget is less than $100k to get necessary 510k approvals and to f
Slide 13: Financial Highlights & Projections
Financial Highlights & Projections 7,000,000 6,000,000 5,000,000 4,000,000 -— 3,000,000 — 2,000,000 -— 4,000,000 04 -1,000,000 -2,000,000 -— -3,000,000 e==Revenue Net Income 2009 2010e 2011e Revenue 288,021 2,000,000 | 6,000,000 Net Income) (2,302,527) | (500,000) | 1,400,000 Copyright © 2010 Wound
Slide 14: Management
Management > Scott Haire, Chairman/CEO, has extensive management experience including experience in the healthcare and technology sectors. Prior to Wound Management, he was President of Preferred Payment Systems and CEO of Medbanc Data Corporation. > Deborah Jenkins Hutchinson, President, Director h
Slide 15: Management, continued
Management, continued >» Cathy Bradshaw, President, Wound Care Innovations, LLC Division. Cathy has over 25 years of healthcare management experience in homecare, pharmacy & infusion services, long term care, and DME, including serving as SE Regional VP at Ivonyx, Inc. (home infusion) and Sr. VP of
Slide 16: Stock Overview
Stock Overview Wound Management Technology, Inc. (WNDM) is a rapidly growing provider of advanced biotechnology products and eHealth technology solutions. = Symbol: WNDM = Exchange: OTC BB = Shares Outstanding: 35,341,938 (2Q 2010) = Estimated Float: 3.3M = Last Trade: $0.38 (11/09/2010) = Market ca
Slide 17: Wound Management Technologies contact
WY, | Wound Management SJ J TECHNOLOGIES, INC. 777 Main Street, Suite 3100 Fort Worth, Texas 76102 USA +1 (817) 820-7080 www.wmgtech.com www.celleraterx.com Deborah Jenkins Hutchinson djenkins@wmgtech.com Copyright © 2010 Wound Management Technologies Inc. 17
Wound Management Technologies — Investor Presentation (November 2010) on 6ix